NAVIGATION
 
> Home
> OPPI Vision
> Office Bearers 
> Committees
> News and Events
> OPPI in Media - 2010 to date - News at a glance
> OPPI Position on IPR
> Pharma Spectrum - Monthly News At A Glance
> OPPI Position Paper on Biosimilars
> OPPI Position on Data Protection
> OPPI Anti - Counterfeiting Guidelines
> A Handy Guide for Road Safety
> OPPI IPR Symposium Videos
> Patents
> Drug Policy & Pricing
> Regulatory
> Links
> India OTC Pharmaceutical Profile 2011
   
 

 

IFPMA Clinical
Trials Portal

IFPMA - Improving
Global Health


OPPI Guidelines on
Cold Chain
Pharmaceutical Products


OPPI - YES Bank Report,
Pharmaceutical Industry:
Vision 2015


OPPI IPR
Symposium Proceedings

 




About Us Members Publications Contact Us Member Login
 
  OPPI NEWS
 

FMHG Market in India – A Close View (Industry Lobbying)
March 16-31, 2009, Express Pharma


The Organisation of Pharmaceutical Producers of India (OPPI) has submitted a list of 11 molecules to the DCI to be excluded from Schedule H paving way for the initiation of responsible self medication as the first line of health management.



            Copyright © 2011. Organisation of Pharmaceutical Producers of India. All Rights Reserved.  |   Disclaimer  |